Nicholas Investment Partners LP Purchases New Position in Xenon Pharmaceuticals Inc. $XENE

Nicholas Investment Partners LP acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 395,844 shares of the biopharmaceutical company’s stock, valued at approximately $23,893,000. Xenon Pharmaceuticals comprises 1.3% of Nicholas Investment Partners LP’s portfolio, making the stock its 14th largest position. Nicholas Investment Partners LP owned about 0.41% of Xenon Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Danske Bank A S purchased a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at $32,000. Kestra Advisory Services LLC purchased a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth $33,000. Osaic Holdings Inc. lifted its holdings in shares of Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at $43,000. Finally, Rockefeller Capital Management L.P. boosted its position in shares of Xenon Pharmaceuticals by 450.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 900 shares during the last quarter. 95.45% of the stock is owned by institutional investors.

Insider Transactions at Xenon Pharmaceuticals

In related news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Steven Gannon sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total transaction of $640,600.00. Following the sale, the director owned 1,870 shares of the company’s stock, valued at $119,792.20. This trade represents a 84.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 12,512 shares of company stock worth $774,088 in the last quarter. Company insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock opened at $60.56 on Tuesday. Xenon Pharmaceuticals Inc. has a one year low of $35.60 and a one year high of $72.66. The stock has a fifty day moving average of $62.48 and a 200 day moving average of $55.92. The stock has a market cap of $5.85 billion, a PE ratio of -12.78 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same period in the previous year, the firm earned ($1.07) earnings per share. As a group, sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

Analysts Set New Price Targets

XENE has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. JPMorgan Chase & Co. upped their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Royal Bank Of Canada dropped their price target on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Needham & Company LLC reduced their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Wells Fargo & Company reissued an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $77.13.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.